Objectives: The purpose of this study was to validate computed tomography measured ECV (ECV) as part of routine evaluation for the detection of cardiac amyloid in patients with aortic stenosis (AS)-amyloid.

Background: AS-amyloid affects 1 in 7 elderly patients referred for transcatheter aortic valve replacement (TAVR). Bone scintigraphy with exclusion of a plasma cell dyscrasia can diagnose transthyretin-related cardiac amyloid noninvasively, for which novel treatments are emerging. Amyloid interstitial expansion increases the myocardial extracellular volume (ECV).

Methods: Patients with severe AS underwent bone scintigraphy (Perugini grade 0, negative; Perugini grades 1 to 3, increasingly positive) and routine TAVR evaluation CT imaging with ECV using 3- and 5-min post-contrast acquisitions. Twenty non-AS control patients also had ECV performed using the 5-min post-contrast acquisition.

Results: A total of 109 patients (43% male; mean age 86 ± 5 years) with severe AS and 20 control subjects were recruited. Sixteen (15%) had AS-amyloid on bone scintigraphy (grade 1, n = 5; grade 2, n = 11). ECV was 32 ± 3%, 34 ± 4%, and 43 ± 6% in Perugini grades 0, 1, and 2, respectively (p < 0.001 for trend) with control subjects lower than lone AS (28 ± 2%; p < 0.001). ECV accuracy for AS-amyloid detection versus lone AS was 0.87 (0.95 for Tc-3,3-diphosphono-1,2-propanodicarboxylic acid Perugini grade 2 only), outperforming conventional electrocardiogram and echocardiography parameters. One composite parameter, the voltage/mass ratio, had utility (similar AUC of 0.87 for any cardiac amyloid detection), although in one-third of patients, this could not be calculated due to bundle branch block or ventricular paced rhythm.

Conclusions: ECV during routine CT TAVR evaluation can reliably detect AS-amyloid, and the measured ECV tracks the degree of infiltration. Another measure of interstitial expansion, the voltage/mass ratio, also performed well.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536272PMC
http://dx.doi.org/10.1016/j.jcmg.2020.05.029DOI Listing

Publication Analysis

Top Keywords

cardiac amyloid
12
bone scintigraphy
12
aortic stenosis
8
perugini grades
8
5-min post-contrast
8
ecv
6
patients
6
identifying cardiac
4
amyloid
4
amyloid aortic
4

Similar Publications

Transthyretin amyloidosis (ATTR) is a rare disease that results in amyloid fibril misfolding and deposition in multiple organs, including the heart, leading to the development of ATTR cardiomyopathy (ATTR-CM), which is associated with poor outcomes. In the last decade, several disease-modifying medications are in advanced stages of clinical development or have been approved to treat ATTR-CM. The purpose of this review is to critically evaluate clinical trial data investigating the use of approved and investigational medications for the treatment of ATTR-CM.

View Article and Find Full Text PDF

Right ventricular coupling predicts cardiopulmonary fitness in cardiac transthyretin amyloidosis.

Amyloid

December 2024

Department of Cardiology, German Heart Centre Munich, TUM University Hospital, School of Medicine and Health, Technical University of Munich, Munich, Germany.

Background: Wild-type transthyretin cardiac amyloidosis (ATTRwt) is an infiltrative disease leading to restrictive cardiomyopathy. We aimed to characterise exercise capacity in ATTRwt and to identify predictors of cardiopulmonary fitness, focusing on echocardiographic and clinical parameters.

Methods: We studied 110 ATTRwt patients from a prospective single-centre registry (2020-2024) by cardiopulmonary exercise testing (CPET).

View Article and Find Full Text PDF

Background And Aims: The positron emission tomography (PET) tracer 18F-florbetaben is a promising diagnostic tool for light-chain cardiac amyloidosis (AL-CA). A greater cardiac uptake might signal more amyloid burden and a worse outcome. We aimed to assess the prognostic significance of 18F-florbetaben uptake in AL-CA.

View Article and Find Full Text PDF

Early Diagnosis and Treatment of Cardiac Amyloidosis by Screening Biopsy During Trigger Finger Release.

J Hand Surg Glob Online

November 2024

Division of Plastic and Reconstructive Surgery, Department of Surgery, University of California Davis, Sacramento, CA.

Patients undergoing trigger release surgery are known to be at increased risk of amyloidosis and heart failure, and therefore, amyloidosis screening during trigger release surgery may facilitate early diagnosis and treatment of cardiac amyloidosis. However, the reported prevalence of amyloid on biopsies taken during trigger release surgery has varied widely, and no biopsy-positive patients in prior studies have been diagnosed with occult cardiac amyloidosis or started on disease-modifying therapy. We review the existing literature on this topic and present a case of a patient with cardiac amyloidosis diagnosed from a biopsy taken during trigger release surgery and subsequently started on disease-modifying therapy.

View Article and Find Full Text PDF

Imaging of cardiac amyloidosis using dynamic F-FPYBF-2 positron emission tomography.

Ann Nucl Med

December 2024

Clinical Research Center, Shiga General Hospital, 5-4-30, Moriyama-Cho, Moriyama, Shiga, 524-8524, Japan.

Purpose: This study aimed to evaluate the diagnostic ability of 5-(5-(2-(2-(2-F-fluoroethoxy) ethoxy) ethoxy) benzofuran-2-yl)-N-methylpyridin-2-amine (F-FPYBF-2) dynamic PET for patients with cardiac amyloidosis (CA).

Methods: The subjects were patients diagnosed with proven amyloidosis (n = 16) including transthyretin cardiac amyloidosis (ATTR-CA) (n = 7) and light chain amyloidosis (AL amyloidosis) (n = 9), of which 4 and 5 with (AL-CA) and without (AL-nCA) cardiac involvement, and 4 control subjects suffering from some symptoms of cardiac failure without amyloidosis (CTL). Thirty minutes dynamic F-FPYBF-2 PET/CT was performed to evaluate the time activity curve and the retention index (mRI) as the ratio of the myocardial SUV at 15 to 5 min.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!